HealthEquity (HQY)
(Real Time Quote from BATS)
$79.49 USD
+0.45 (0.57%)
Updated Apr 26, 2024 10:30 AM ET
3-Hold of 5 3
C Value B Growth A Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
HQY 79.49 +0.45(0.57%)
Will HQY be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for HQY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HQY
Here's Why HealthEquity (HQY) is a Strong Growth Stock
Here's Why HealthEquity (HQY) is a Strong Growth Stock
HQY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Reasons Why You Should Retain HealthEquity (HQY) Stock for Now
Why HealthEquity (HQY) is a Top Growth Stock for the Long-Term
Why HealthEquity (HQY) is a Top Growth Stock for the Long-Term
Other News for HQY
HealthEquity Board Re-Nominates Directors, Reduces Size
IWO: Unconvincing Small Cap Growth ETF
J.P. Morgan’s Analyst Focus List - 5 adds and 1 removal
Analysts Offer Insights on Healthcare Companies: Edgewise Therapeutics (EWTX), Healthequity (HQY) and Nuvation Bio (NUVB)
HealthEquity Expands Portfolio with Conduent Acquisition